Prevalence of active infection with Chlamydia pneumoniae and human cytomegalovirus in patients with type II diabetes mellitus
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
17702468
DOI
10.1007/bf02931311
Knihovny.cz E-resources
- MeSH
- Chlamydophila pneumoniae MeSH
- Cytomegalovirus Infections complications epidemiology immunology MeSH
- Diabetes Mellitus, Type 2 complications microbiology MeSH
- Chlamydophila Infections complications epidemiology immunology MeSH
- Cardiovascular Diseases complications MeSH
- Diabetes Complications epidemiology microbiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Prevalence MeSH
- Seroepidemiologic Studies MeSH
- Case-Control Studies MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
By promoting the inflammatory process in the arterial wall, Chlamydia pneumoniae (CPN) and human cytomegalovirus (CMV) participate in the pathogenesis of cardiovascular disease (CVD). Since patients with diabetes mellitus (DM) are at high risk of CVD, we studied markers of CMV and CPN infection in DM patients as possible predictors of cardiovascular complications. The seroprevalence rates of CMV in 44 DM patients and matched controls were 74 and 88%, respectively. Compared with controls, patients showed lower titers of IgG against CMV (p < 0.001) and higher titers of genus-specific IgA against CPN (p = 0.006). The titers of genus-specific IgG and prevalence rates of type-specific anti-CPN IgA, IgG or IgM were similar in both DM patients and controls. Serological markers of either active or recent CPN infection were detected in 54% of patients and 59% of controls. However, CPN DNA was not detected in the blood of any DM patient. CMV DNA was found in the blood of 1 (2.3%) patient. The results do not indicate an increased rate of CMV or CPN infection in patients with type II DM.
See more in PubMed
Trends Immunol. 2004 Jan;25(1):4-7 PubMed
J Clin Microbiol. 2001 Apr;39(4):1368-77 PubMed
Clin Infect Dis. 1999 Apr;28(4):746-9 PubMed
J Clin Microbiol. 2001 May;39(5):1859-64 PubMed
Lancet. 1997 Aug 9;350(9075):430-6 PubMed
Clin Infect Dis. 2005 Feb 15;40(4):628-31 PubMed
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65 PubMed
J Gen Virol. 1993 Dec;74 ( Pt 12):2699-707 PubMed
J Immunol. 2002 Feb 1;168(3):1435-40 PubMed
J Clin Microbiol. 2003 Sep;41(9):4049-53 PubMed
Clin Infect Dis. 2005 Apr 1;40(7):990-6 PubMed
Clin Infect Dis. 2001 Aug 15;33(4):492-503 PubMed
Cent Eur J Public Health. 2003 Jun;11(2):102-6 PubMed
